Methamphetamine-associated psychosis: a new health challenge in Iran
1 Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, No.669, South Karegar Ave, Tehran, Iran
2 Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada
3 Iranian National Center for Addiction Studies (INCAS), School of Advanced Technologies in Medicine (SATM), Tehran University of Medical Sciences, Tehran, Iran
DARU Journal of Pharmaceutical Sciences 2013, 21:30 doi:10.1186/2008-2231-21-30Published: 11 April 2013
The rapidly growing popularity of methamphetamine use in Iran has posed a new health challenge to the Iranian health sector. Methamphetamine-associated psychosis (MAP) has been frequently reported in Iran in recent years. Although methamphetamine use and MAP are considerable health problems in Iran but there is still a need to conduct epidemiological studies on the prevalence of MAP and its health-related problems. The present paper emphasizes that health policy makers should consider the immediate needs of drug users, their families and the community to be informed about the detrimental health effects associated with MAP. Although MAP could be managed by prescribing benzodiazepines and psychiatric medications but the most effective regime for stabilizing patients with MAP still needs to be studied in Iran. Constant collaborations among psychiatric services and outpatient psychotherapeutic services should be established to successfully manage MAP in Iran. Iranian clinicians especially emergency medicine specialists should be informed about the differences between the two forms of transient and recurrent MAP in order to implement appropriate pharmacological therapies to manage MAP. It is hoped that special training courses are designed and implemented by health policy makers to inform clinicians, health providers and especially emergency medicine specialists to effectively deal with MAP.